# SEZanne (NCT07155174)

> A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07155174
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: AbbVie
- Conditions: Small Cell Lung Cancer
- Interventions: ABBV-706; Atezolizumab; Etoposide; Carboplatin; Carboplatin; Lurbinectedin
- Enrollment: 180
- Primary outcome: Number of Participants with Adverse Events (AE)s
- Primary outcome: Progression-Free Survival (PFS) Based on Investigator Assessment

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=sezanne-nct07155174